{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:37:37Z","timestamp":1786718257071,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijp.ijp_846_16","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:38:06Z","timestamp":1522024686000},"page":"451","source":"Crossref","is-referenced-by-count":9,"title":["Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study"],"prefix":"10.4103","volume":"49","author":[{"given":"G","family":"Shivaprakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KarthikS","family":"Udupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Sarayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LC","family":"Pallavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.228454-1","first-page":"e352","volume-title":"Recommendations for screening and early detection of common cancers in India","author":"Rajaraman","year":"2015","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0253-7613.228454-2","first-page":"191","volume-title":"Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice","author":"Hesketh","year":"1999","journal-title":"Oncologist"},{"key":"key-10.4103\/0253-7613.228454-3","first-page":"1055","volume-title":"Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists","author":"De","year":"1997","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0253-7613.228454-4","first-page":"381","volume-title":"Antiemetics: American society of clinical oncology focused guideline update","author":"Hesketh","year":"2016","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.228454-5","unstructured":"NCCN. Clinical Practice Guidelines in Oncology. Antiemesis, Version 2. 2016. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. [Last accessed on 2016 Oct 27]."},{"key":"key-10.4103\/0253-7613.228454-6","unstructured":"MASCC Antiemetic Guidelines. Hillerod, Denmark: Multinational Association of Supportive Care in Cancer, 2013. Available from: http:\/\/www.mascc.org\/antiemetic-guidelines. [Last accessed on 2016 Dec 27]."},{"key":"key-10.4103\/0253-7613.228454-7","first-page":"595894","volume-title":"Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting","author":"Navari","year":"2015","journal-title":"Biomed Res Int"},{"key":"key-10.4103\/0253-7613.228454-8","first-page":"2822","volume-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.228454-9","first-page":"711","volume-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"key-10.4103\/0253-7613.228454-10","unstructured":"CIMS India: Aprepitant. Available from: https:\/\/www.mims.com\/india\/drug\/info\/aprecap\/aprecap%20kit. [Last accessed on 2016 Oct 27]."},{"key":"key-10.4103\/0253-7613.228454-11","first-page":"180","volume-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","author":"Navari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/0253-7613.228454-12","first-page":"148","volume-title":"Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: The MASCC antiemesis tool","author":"Molassiotis","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"key-10.4103\/0253-7613.228454-13","unstructured":"Common Terminology Criteria for Adverse Events Ctcae v 4.03. United States: National Cancer Institute; 2010. Available from: http:\/\/www.hrc.govt.nz\/sites\/default\/files\/CTCAE%20manual%20-%20DMCC.pdf. [Last accessed on 2017 Feb 11]."},{"key":"key-10.4103\/0253-7613.228454-14","first-page":"21","volume-title":"Breast cancer care in India: The current scenario and the challenges for the future","author":"Agarwal","year":"2008","journal-title":"Breast Care (Basel)"},{"key":"key-10.4103\/0253-7613.228454-15","first-page":"9","volume-title":"High prevalence of tobacco use, alcohol use and overweight in a rural population in Tamil Nadu, India","author":"Kaur","year":"2011","journal-title":"J Postgrad Med","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3859","issn-type":"print"},{"key":"key-10.4103\/0253-7613.228454-16","first-page":"283","volume-title":"Regular use of alcohol and tobacco in India and its association with age, gender, and poverty","author":"Neufeld","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"key-10.4103\/0253-7613.228454-17","unstructured":"Bruce AC, Bertino J, Cleary J, Ortiz T, Lane A, Jeffrey GS,et al. Cytotoxic agents. In: Brunton LL, Bruce Chabner BA, Knollman BJ, editors. Goodman & Gilman's The Phgroupacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 1677-730."},{"key":"key-10.4103\/0253-7613.228454-18","first-page":"188","volume-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"key-10.4103\/0253-7613.228454-19","first-page":"1143","volume-title":"Olanzapine for chemotherapy-induced nausea and vomiting: A systematic review","author":"Hocking","year":"2014","journal-title":"Support Care Cancer"},{"key":"key-10.4103\/0253-7613.228454-20","first-page":"3439707","volume-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: A Pilot study from South India","author":"Babu","year":"2016","journal-title":"Chemother Res Pract"},{"key":"key-10.4103\/0253-7613.228454-21","first-page":"299","volume-title":"Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany","author":"Lordick","year":"2007","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0253-7613.228454-22","first-page":"229","volume-title":"Neurotransmitter functions of mammalian tachykinins","author":"Otsuka","year":"1993","journal-title":"Physiol Rev"},{"key":"key-10.4103\/0253-7613.228454-23","first-page":"1853","volume-title":"Aprepitant: A review of its use in the prevention of nausea and vomiting","author":"Curran","year":"2009","journal-title":"Drugs"},{"key":"key-10.4103\/0253-7613.228454-24","first-page":"187","volume-title":"Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control","author":"Schnell","year":"2003","journal-title":"Oncologist"},{"key":"key-10.4103\/0253-7613.228454-25","first-page":"1759","volume-title":"Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone","author":"Campos","year":"2001","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0253-7613.228454-26","first-page":"v232","volume-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.228454-27","first-page":"4189","volume-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","author":"Basch","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:33:00Z","timestamp":1786714380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_846_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"alternative-id":["228454"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_846_16","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}